Guangzhou Daguang Pharmaceutical Co., Ltd.

Primary Objective: To investigate the pharmacokinetic characteristics of a single oral dose of bromocriptine mesylate tablets (2.5 mg) manufactured by Guangzhou Daguang Pharmaceutical Co., Ltd., and bromocriptine mesylate tablets (2.5 mg) (trade name: Parlodel®) manufactured by Bridging Pharma GmbH, in healthy Chinese subjects after a meal, and to evaluate their bioequivalence. Secondary Objective: To evaluate the safety of a single oral dose of bromocriptine mesylate tablets (2.5 mg) in healthy Chinese subjects, both the test and reference formulations.

The primary objective was to investigate the in vivo pharmacokinetic characteristics of a single oral dose of 2 mg polytinol tablets manufactured by Guangzhou Daguang Pharmaceutical Co., Ltd. and a 2 mg polytinol tablets manufactured by Fuji Pharmaceutical Co., Ltd. (trade name: URECE®) under fasting and fed conditions in healthy Chinese volunteers, and to evaluate the bioequivalence of the two formulations. The secondary objective was to evaluate the safety of a single oral dose of the test and reference formulations of 2 mg polytinol tablets in healthy Chinese volunteers.

The primary objective was to investigate the pharmacokinetic parameters and relative bioavailability of Vericigum tablets (developed by Guangzhou Daguang Pharmaceutical Co., Ltd.) as the test formulation and Vericigum tablets (trade name: Verquvo®/Yu Ke Tong®) produced by Bayer AG as the reference formulation after single-dose administration of the two formulations in the fasting and fed states, and to evaluate their bioequivalence. The secondary objective was to evaluate the safety of the test and reference formulations of Vericigum tablets in healthy Chinese participants after single oral administration in the fasting and fed states.